LiteFold makes its private AI drug-discovery platform generally available

LiteFold announced general availability of a private AI platform for drug discovery and scientific R&D, combining agent workflows, biomolecular design and molecular simulations. The company describes on-premises or private-cloud deployment and enterprise licensing or services; no public self-serve model or model weights were identified. Benchmarks and performance claims on the company site are vendor-reported.